Skip to content
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Hematology

The Diagnostic Pathway and Lab Tests

At a Glance

Routine clotting tests can be normal in the bleeding form of a familial THBD disorder, so diagnosis may require specialized clotting studies. For aHUS or TMA, doctors combine platelet, red-cell, kidney, ADAMTS13, infection, and genetic testing.

Navigating the diagnosis of a THBD mutation is uniquely challenging because the standard tests used in most clinics often fail to capture the problem. Depending on whether your mutation causes bleeding or clotting, your doctors will need to follow two very different diagnostic paths.

The Diagnostic Paradox of the Bleeding Type (TM-AC)

If you have the bleeding version of this condition (TM-AC), your laboratory results might actually look “too good” on paper.

Routine tests like the PT (Prothrombin Time) and aPTT (activated Partial Thromboplastin Time) measure how quickly your blood starts to form a clot [1]. In people with TM-AC, the “start” of the clotting process is usually normal, so these tests often come back within the standard range [2]. The problem occurs later: the excess thrombomodulin prevents the clot from growing and stabilizing [3].

To find the issue, your specialist may need to order non-routine tests (note these are specialized send-out tests not universally standardized):

  • Soluble Thrombomodulin (sTM) Levels: This measures the amount of thrombomodulin floating in your plasma. In some families with this mutation, these levels are significantly higher than normal [4].
  • Thrombin Generation Assay (TGA): This specialized test looks at the entire “lifespan” of a clot, rather than just the beginning. It often shows that the total amount of thrombin (the “clotting engine”) being produced is much lower than it should be [3][4].
  • Clot Lysis Assessment: This checks how quickly your body dissolves a clot. In some patients, the mutation causes clots to break down too slowly or too quickly, depending on the specific variant [3].

The Clotting/aHUS Diagnostic Pathway

When a patient presents with the clotting phenotype (aHUS or TMA), the diagnosis is treated as a medical emergency. Doctors look for a specific “triad” of symptoms in your blood and urine [5]:

  1. Low Platelets (Thrombocytopenia): Your body is using up platelets to form tiny, unnecessary clots [6].
  2. Hemolysis (Red Blood Cell Destruction): As red blood cells try to squeeze past these tiny clots, they get shredded. Doctors look for “helmet-shaped” cell fragments called schistocytes on a blood smear [5][7].
  3. Kidney Injury: High levels of creatinine in the blood or protein/blood in the urine indicate that the kidneys are being damaged by these micro-clots [8].
    This is a useful pattern, but it is not required in every TMA presentation; renal-limited TMA and cases with modest thrombocytopenia can occur [5].

Ruling Out Other Conditions

Because aHUS looks almost identical to other dangerous conditions, your team must perform “rule-out” testing immediately:

  • ADAMTS13 Activity: This is a critical test. If your ADAMTS13 activity is below 10%, it strongly supports severe TTP (Thrombotic Thrombocytopenic Purpura), which requires immediate specialist management. If the activity is above 10%, it makes classic TTP less likely, but it does not establish aHUS; other secondary TMAs remain possible. Suspected TTP requires immediate treatment, and treatment decisions should never wait for a delayed ADAMTS13 result. [9][10].
  • Shiga Toxin Testing: This rules out a common type of HUS caused by E. coli bacteria, which usually involves severe diarrhea [11].

The Role of Genetic Panels

Because THBD is just one of many genes that can cause these issues, doctors often use a Complement-Mediated TMA Panel. This panel looks at THBD alongside about a dozen other genes (like CFH, CFI, and C3) [12][13].

It is important to remember that about 40% of people (depending on the population, assay, and panel) with clear clinical symptoms of aHUS will have a “negative” genetic test [14]. This does not mean you don’t have the condition; a negative genetic panel does not exclude aHUS, and a THBD VUS does not confirm it. Your doctor will prioritize your physical symptoms and laboratory markers (like LDH and haptoglobin) over the genetic results when making urgent treatment decisions [15][16].

Common questions in this guide

Can normal PT and aPTT tests rule out a bleeding-related THBD disorder?
No. In the bleeding form, these routine tests may be normal because they measure the beginning of clot formation, while the problem affects later clot growth and stability. A specialist may consider a thrombin generation assay or soluble thrombomodulin measurement.
What findings raise concern for aHUS or another TMA?
Doctors look for low platelets, destruction of red blood cells, and kidney injury, often reflected by schistocytes, elevated creatinine, or protein or blood in the urine. Not every person has all three findings; kidney-limited TMA and modest thrombocytopenia can occur.
Why is ADAMTS13 testing important when TTP is suspected?
An ADAMTS13 activity below 10% strongly supports severe thrombotic thrombocytopenic purpura, or TTP, which is a medical emergency requiring immediate specialist management. A result above 10% makes classic TTP less likely but does not prove aHUS, and urgent treatment decisions should not wait for a delayed result.
Does a negative THBD or complement genetic panel rule out aHUS?
No. Many people with clinically diagnosed aHUS have no identifiable disease-causing variant, so a negative panel does not exclude it. A THBD variant of uncertain significance also cannot confirm the diagnosis; symptoms and laboratory findings remain central.
What does Shiga toxin testing check for?
Shiga toxin testing looks for a bacterial cause of hemolytic uremic syndrome, often associated with E. coli and severe diarrhea. A positive result points toward infection-associated HUS, although clinicians interpret it alongside the person's other symptoms and test results.

Get notified when new evidence is published on Familial thrombomodulin anomalies.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (16)
  1. 1

    How to investigate mild to moderate bleeding disorders and bleeding disorder of unknown cause.

    Casini A, Gebhart J

    International journal of laboratory hematology 2024; (46 Suppl 1()):27-33 doi:10.1111/ijlh.14266.

    PMID: 38454298
  2. 2

    Thrombin Generation Measurement: A Novel Diagnostic and Prognostic Approach for Identifying Early-Stage Disseminated Intravascular Coagulation in Individuals with Sepsis.

    Turkal R, Çevlik T, Tekin AF, et al.

    Journal of intensive care medicine 2026; (41(9)):904-915 doi:10.1177/08850666261423151.

    PMID: 41707669
  3. 3

    Altered fibrinolysis in autosomal dominant thrombomodulin-associated coagulopathy.

    Burley K, Whyte CS, Westbury SK, et al.

    Blood 2016; (128(14)):1879-1883 doi:10.1182/blood-2016-05-716092.

    PMID: 27436851
  4. 4

    A new pedigree with thrombomodulin-associated coagulopathy in which delayed fibrinolysis is partially attenuated by co-inherited TAFI deficiency.

    Westbury SK, Whyte CS, Stephens J, et al.

    Journal of thrombosis and haemostasis : JTH 2020; (18(9)):2209-2214 doi:10.1111/jth.14990.

    PMID: 32634856
  5. 5

    Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial.

    Fakhouri F, Hourmant M, Campistol JM, et al.

    American journal of kidney diseases : the official journal of the National Kidney Foundation 2016; (68(1)):84-93.

    PMID: 27012908
  6. 6

    [CME: Diagnostic Approach and Management of Thrombotic Microangiopathy].

    Sutter T, Fehr T, Venzin R

    Praxis 2022; (111(14)):771-777 doi:10.1024/1661-8157/a003927.

    PMID: 36285415
  7. 7

    Atypical Hemolytic Uremic Syndrome Presenting as Acute Heart Failure-A Rare Presentation: Diagnosis Supported by Skin Biopsy.

    Kichloo A, Chugh SS, Gupta S, et al.

    Journal of investigative medicine high impact case reports 2019; (7()):2324709619842905 doi:10.1177/2324709619842905.

    PMID: 31010328
  8. 8

    Case Report: Atypical hemolytic uremic syndrome triggered by Rhinovirus/Enterovirus infection with cutaneous thrombotic microangiopathy requiring surgical management.

    Shen J, Cai K, Kang W, et al.

    Frontiers in pediatrics 2026; (14()):1973640 doi:10.3389/fped.2026.1973640.

    PMID: 42973488
  9. 9

    Medical consult: aHUS, TTP? How to distinguish and what to do.

    Story CM, Gerber GF, Chaturvedi S

    Hematology. American Society of Hematology. Education Program 2023; (2023(1)):745-753 doi:10.1182/hematology.2023000501.

    PMID: 38066937
  10. 10

    Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand.

    Fox LC, Cohney SJ, Kausman JY, et al.

    Nephrology (Carlton, Vic.) 2018; (23(6)):507-517 doi:10.1111/nep.13234.

    PMID: 29419916
  11. 11

    Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis.

    Laurence J, Haller H, Mannucci PM, et al.

    Clinical advances in hematology & oncology : H&O 2016; (14 Suppl 11(11)):2-15.

    PMID: 27930620
  12. 12

    Combined study of ADAMTS13 and complement genes in the diagnosis of thrombotic microangiopathies using next-generation sequencing.

    Fidalgo T, Martinho P, Pinto CS, et al.

    Research and practice in thrombosis and haemostasis 2017; (1(1)):69-80 doi:10.1002/rth2.12016.

    PMID: 30046676
  13. 13

    Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics.

    Fakhouri F, Frémeaux-Bacchi V

    Nature reviews. Nephrology 2021; (17(8)):543-553 doi:10.1038/s41581-021-00424-4.

    PMID: 33953366
  14. 14

    Atypical hemolytic uremic syndrome: Consensus of diagnosis and treatment in Taiwan.

    Tseng MH, Lin SH, Tsai JD, et al.

    Journal of the Formosan Medical Association = Taiwan yi zhi 2023; (122(5)):366-375 doi:10.1016/j.jfma.2022.10.006.

    PMID: 36323601
  15. 15

    Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome.

    Lee H, Kang E, Kang HG, et al.

    The Korean journal of internal medicine 2020; (35(1)):25-40 doi:10.3904/kjim.2019.388.

    PMID: 31935318
  16. 16

    [Ultra-early administration of eculizumab in a child with atypical hemolytic uremic syndrome: a case report].

    Guo DD, Xiao YX, Wang WR, et al.

    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 2025; (27(11)):1408-1413 doi:10.7499/j.issn.1008-8830.2503084.

    PMID: 41250542

This page explains diagnostic testing for familial thrombomodulin anomalies for educational purposes and does not constitute medical advice. Suspected TTP or TMA requires urgent evaluation, so follow your healthcare team's instructions promptly.